Comparison of the chondrogenic potential of eBMSCs and eUCMSCs in response to selected peptides and compounds.
Authors: Ajeeb Boushra, Kiyotake Emi A, Keefe Peggy A, Phillips Jennifer Nikki, Hatzel Jennifer N, Goodrich Laurie R, Detamore Michael S
Journal: BMC veterinary research
Summary
# Editorial Summary Cartilage repair in horses remains clinically problematic, with most surgical interventions producing inferior fibrocartilage rather than functional hyaline cartilage and predisposing to post-traumatic osteoarthritis. Whilst bone marrow-derived mesenchymal stem cells (eBMSCs) are the established cell source for cartilage regeneration therapies, umbilical cord matrix cells (eUCMSCs) represent an attractive alternative due to their non-invasive harvest and immunological advantages. Boushra and colleagues compared the chondrogenic capacity of both cell sources when stimulated by four bioactive factors—peptides CM10 and CK2.1, and small-molecule compounds kartogenin and SM04690—alongside conventional induction protocols using dexamethasone and TGF-β3 in varying culture conditions (monolayer versus spheroid, hypoxia versus normoxia). The research provides equine professionals with evidence-based comparative data on alternative chondroinductive strategies that could improve cartilage regeneration outcomes without relying on expensive recombinant growth factors. These findings have direct relevance for developing more effective, cost-efficient cell-based therapies for managing articular cartilage injuries and potentially reducing the incidence of post-traumatic osteoarthritis in equine patients.
Read the full abstract on PubMed
Practical Takeaways
- •Novel peptides and small compounds may offer growth factor-free alternatives for cartilage repair therapies in horses, potentially improving accessibility and cost of cell-based treatments
- •Umbilical cord matrix cells could provide a practical advantage over bone marrow harvesting for allogeneic cartilage regeneration strategies in equine practice
- •Culture conditions (monolayer vs. spheroid, hypoxia vs. normoxia) significantly influence stem cell chondrogenic potential and should be optimized for clinical translation
Key Findings
- •Both eBMSCs and eUCMSCs demonstrated chondrogenic potential in response to selected peptides (CM10, CK2.1) and compounds (kartogenin, SM04690)
- •eBMSCs showed differential chondroinductive responses between monolayer and spheroid culture systems under hypoxic versus normoxic conditions
- •Dexamethasone and TGF-β3 modulated chondrogenic differentiation in eBMSCs with culture conditions influencing outcome
- •eUCMSCs represent a non-invasive alternative cell source with comparable chondrogenic potential to bone marrow-derived cells